The death of Henri Termeer, former chief executive of trailblazing biotech company Genzyme, has prompted a wave of tributes from across the industry.
US trade group the Biotechnology Innovation Organization (BIO) has led the praise for Dutch-born Dr Termeer, who was credited for being the longest-serving CEO in biotech. He led Genzyme from 1981 to 2011, when the company was acquired by French drug major Sanofi (Euronext: SAN).
"Few people have had as profound an impact as Henri Termeer on the science of biotechnology and the patients who depend on it"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze